Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection

Phase 3 Terminated 154 enrolled Sun Yat-sen University

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This prospective multicenter non-randomized controlled study evaluates the efficacy and safety of treatment with Sorafenib (Nevaxar) in patients with hepatocellular carcinoma with microvascular invasion after radical resection compared to conventional therapies.

Timeline

Start: 2016-06-01
Primary completion: 2019-08-31
Completion: 2020-01-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sorafenib	Small molecule	400 mg	Oral

Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection

Summary

Timeline

Drugs

Indications